Neuropace, Inc.
Key Metrics
- Previous Close
- $8.20
- 52-Week Range
- $5.46 – $19.60
- Market Cap
- $283.19M
- P/E (TTM)
- —
- EPS (TTM)
- -0.56
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 24.61
- PEG Ratio
- —
- Return on Equity
- -96.97%
- Return on Assets
- -6.31%
- Gross Margin
- 77.84%
- Operating Margin
- -9.55%
- Profit Margin
- -17.72%
- Current Ratio
- 5.26
- Debt/Equity
- 6.05
- Total Debt
- $69.54M
- Free Cash Flow
- $-2.41M
- Revenue Growth
- -1.10%
- Earnings Growth
- —
- Enterprise Value
- $303.50M
Market Snapshot
About
Neuropace develops and commercializes the RNS System, a brain-responsive neurostimulation device for treating drug-resistant focal epilepsy through personalized, closed-loop therapy.